Advertisement
Advertisement

HIV Care Today


Where Are the DHHS HIV Treatment Guidelines for Clients Over 50 Years Old?
By Bethsheba Johnson, G.N.P.-B.C., A.A.H.I.V.S.
October 3, 2011

As I just celebrated another birthday and relocated to Houston, Texas, to a nice home with lots and lots of stairs, I couldn't help but think about aging. My knees and back are aching. I'm just plain tired! I know that in the clinical setting you are hearing similar complaints among your older clients. We can be an achy mess as we age! For our clients, is it the untreated/inadequately treated HIV, aging, or both?

Read more …


Warning: Viral Replication Is Hazardous to Your Health
By Paul E. Sax, M.D.
September 24, 2011

When studies evaluate the prognostic importance of measuring HIV viral load, they generally do so by assessing a single measurement rather than values obtained longitudinally. One obvious limitation of this approach is that baseline VL poorly predicts outcome after ART initiation -- a finding in stark contrast to the original description of VL from the MACS cohort prior to effective HIV therapy.

Read more …


"Novel" Approaches to Initial HIV Therapy
By Paul E. Sax, M.D.
September 6, 2011

It's been several years since the "preferred" or "recommended" initial regimens for HIV treatment have been consolidated into one of the following four:

Read more …


Addressing the Gaping Hole in HIV Prevention: A Plea for Public Health Action
By Lisa Fitzpatrick, M.D., M.P.H.
September 6, 2011

The CDC has yet again released a report highlighting the growing HIV disparity in young, black men who have sex with men (MSM). Over a decade ago, similar attention was called to what then appeared to be a public health blemish in this population. Because our prevention efforts have been largely cosmetic and woefully inadequate, the 7% increase in the infection rate among black MSM suggests this blemish is now a gushing and gaping wound requiring urgent public health action.

Read more …


A "Gut Feeling" Emerges in HIV
By Nelson Vergel, B.S.Ch.E., M.B.A.
September 6, 2011

The effects of HIV and highly active antiretroviral therapy [HAART] on gut health were highlighted recently at the 13th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV in Rome, Italy.

Read more …


A Reason to Continue Restrictive HIV Testing Laws? Not Really
By Paul E. Sax, M.D.
August 19, 2011

The pending HIV legislation is much on my mind these days, for reasons I outlined here. Bottom line is that I don't think it's good for patient care, and we're missing a real opportunity to make things better here in the Bay State.

Read more …


Next Single-Pill HIV Treatment Approved, and It's Not Called "B-Tripla"
By Paul E. Sax, M.D.
August 11, 2011

One famous HIV clinician/clinical researcher likens co-formulated TDF/FTC/EFV (Atripla) to a "Godzilla," so dominant has the treatment become as initial therapy for HIV. He bases his comments on this study done at his institution, showing that in 2007, fully 85% of patients starting treatment in their clinic began TDF/FTC/EFV.

Read more …


Why the Proposed Massachusetts HIV Testing Bill Is Bad for Patients
By Paul E. Sax, M.D.
August 9, 2011

First, there's the requirement for written informed consent, something that every state (except a couple) has wisely abandoned. Second, it's more than a testing law -- it's also an HIV privacy law, which is arguably unnecessary in this post HIPAA era and has all sorts of unintended consequences.

Read more …


Really Rapid Review -- IAS 2011 Rome
By Paul E. Sax, M.D.
July 28, 2011

Just back from IAS 2011 (which was followed, I'm thrilled to say, with a visit to perhaps the most beautiful region in the world). Here is a Really Rapid ReviewTM of the meeting, with apologies ahead of time for lack of organization and (even more likely) leaving out something important. FYI, the abstracts are online here; I'm sure there's a place on the meeting homepage that has the same link, but I can't seem to find it.

Read more …


Should HIV Meds for HIV-Uninfected People Be a Priority? And Other PrEP Questions
By Jeannie Wraight
July 21, 2011

Groundbreaking results of two large pre-exposure prophylaxis (PrEP) studies may lead to a new prevention option to reduce HIV transmission. Data released on two PrEP studies showed high levels of protection against HIV infection when tenofovir (Viread) or Truvada (tenofovir and emtricitabine) were taken daily by HIV-uninfected individuals at high risk for infection.

Read more …

 < Prev  |  1  |  …  |  8  |  9  |  10  |  11  |  12  |  13  |  Next > 

Get email notifications every time HIV Care Today is updated.



This article was provided by TheBodyPRO.com.
 

Advertisement